Safety and Pharmacokinetics Study of Linzagolix in Female Subjects With Normal and Impaired Hepatic Function
Status:
Completed
Trial end date:
2019-11-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to assess the pharmacokinetics (PK) of linzagolix in
subjects with varying degrees of impaired hepatic function compared to match control subjects
with normal hepatic function